XNAS
PRTG
Market cap8mUSD
May 27, Last price
7.98USD
1D
1.14%
1Q
77.33%
Jan 2017
-38.62%
IPO
-66.75%
Name
Portage Biotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
33.37%
Rev. gr., 5y
%
Revenues
0k
Net income
-75m
L-27.98%
CFO
-14m
L+18.42%
Earnings
Aug 25, 2025
Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 18,253 | 16,575 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (18,253) | (16,575) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (10,548) | (17,856) | |||||||
Tax Rate | |||||||||
NOPAT | (7,705) | 1,281 | |||||||
Net income | (75,339) -27.98% | (104,611) 445.73% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,028 | 2,982 | |||||||
BB yield | -52.61% | -5.99% | |||||||
| Debt | |||||||||
Debt current | 40 | ||||||||
Long-term debt | 54 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,564 | 11,305 | |||||||
Net debt | (4,934) | (13,438) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (14,297) | (12,073) | |||||||
CAPEX | (3) | ||||||||
Cash from investing activities | 2,812 | (617) | |||||||
Cash from financing activities | 5,968 | (117) | |||||||
FCF | (9,105) | 3,343 | |||||||
| Balance | |||||||||
Cash | 5,028 | 10,545 | |||||||
Long term investments | 2,893 | ||||||||
Excess cash | 5,028 | 13,438 | |||||||
Stockholders' equity | 3,329 | 54,191 | |||||||
Invested Capital | 1,611 | 73,262 | |||||||
ROIC | 1.24% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 20,340 | 16,119 | |||||||
Price | 0.56 -81.77% | 3.09 -52.97% | |||||||
Market cap | 11,458 -77.00% | 49,808 -41.95% | |||||||
EV | 5,831 | 35,720 | |||||||
EBITDA | (18,199) | (16,574) | |||||||
EV/EBITDA | |||||||||
Interest | 32 | 9 | |||||||
Interest/NOPBT | |||||||||